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PEMANTAUAN TERAPEUTIK UBAT DALAM TERAPI GANTIAN 
METHADONE (TGM) : SUATU PENILAIAN TERHADAP FAKTOR GENETIK 
YANG MEMPENGARUHI KEBERKESANAN KLINIKAL DAN KEPEKATAN 
METHADONE DARAH (SERUM) 
 
ABSTRAK 
Pengenalan: Terapi Gantian Methadone (TGM) telah digunakan secara meluas dan 
berfungsi untuk mengelakkan berlakunya gejala penarikan dalam kalangan 
penyalahguna dadah jenis opiat. Ia merupakan salah satu daripada kaedah pendekatan 
“pengurangan kemudaratan” (harm reduction) bagi menurunkan kadar penularan 
jangkitan melalui darah dalam komuniti terutamanya HIV AIDS yang boleh membawa 
maut. Walau bagaimanapun, proses penentuan dos yang optimum bagi setiap pesakit 
adalah sukar dan mencabar kerana ia menunjukkan kepelbagaian aktiviti farmakologi 
yang tinggi dalam individu yang berbeza. Kajian ini menghuraikan hubungkait di antara 
kepekatan methadone darah (Ctrough) dengan dos harian pesakit dan keberkesanan yang 
dikehendaki iaitu keterukkan gejala penarikan dan ujian pengesahan air kencing bagi 
pengambilan dadah terlarang. Hubungan antara pelbagai haplotaip gen CYP2B6 dengan 
kepekatan methadone darah dan variasi polimorfisme nukleotida tunggal OPRM1 
(A118G) dengan tahap keberkesanan klinikal yang diukur juga dikaji.  
Kaedah: Seramai 115 orang pesakit melepasi ujian saringan dan menandatangani 
borang persetujuan menyertai kajian. Sampel darah diambil bagi tujuan penentuan 
genotaip CYP2B6 dan OPRM1 (sekali) dan untuk penentuan kepekatan methadone 
darah (setiap kali proses pengambilan data). Kepekatan methadone darah ditentukan 
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melalui kaedah ELISA dan penentuan genotaip ditentukan menggunakan kaedah PCR. 
Analisis statistik yang bersesuaian diaplikasi sewajarnya.  
Keputusan: Dos methadone didapati mempunyai hubungkait yang sederhana dan 
positif dengan tahap kepekatan methadone darah (r=0.4, p<0.001), dengan hanya sekitar 
20% perubahan yang berlaku dalam kepekatan methadone darah dapat dikaitkan dengan 
perubahan yang berlaku pada dos (r
2
=0.16-0.19, p<0.05) walaupun setelah mengambil 
kira faktor-faktor persekitaran pesakit yang mungkin akan mempengaruhi kedua-dua 
pembolehubah tersebut. Walau bagaimanapun, kepekatan methadone darah 
menunjukkan hubungkait yang lemah dengan keterukkan gejala penarikan atau 
pengambilan dadah terlarang. Manakala dos pula, tiada menunjukkan sebarang 
hubungkait dengan kedua-dua keberkesanan klinikal tersebut. Kajian terhadap gen 
CYP2B6 mendapati pesakit dengan variasi CYP2B6*6 mempunyai min kepekatan 
methadone darah terubahsuai (log Ctrough/dose) yang lebih tinggi berbanding pesakit 
dengan haplotype CYP2B6*1 (wildtype). Kajian terhadap gen OPRM1 pada lokus 118 
seterusnya menunjukkan pesakit dengan variasi GG didapati tidak menggunakan dadah 
terlarang pada tahap kepekatan methadone yang rendah iaitu di bawah paras 250ng/ml 
berbanding pesakit dengan genotaip AA (wildtype) (p<0.05).  
Kesimpulan: Gen CYP2B6 dan OPRM1 dengan polimorfisme nukleotida tunggal pada 
lokus 118 mungkin berupaya menghuraikan sebahagian variasi kepekatan methadone 
darah dan keberkesanan klinikal. Namun, aplikasinya dalam pendekatan pemantauan 
terapeutik ubat (methadone) bagi tujuan pengindividualan dos methadone berasaskan 
keberkesanan klinikal didapati adalah tidak sesuai. 
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THERAPEUTIC DRUG MONITORING IN METHADONE MAINTENANCE 
THERAPY (MMT): AN EVALUATION OF GENETIC FACTORS 
INFLUENCING CLINICAL OUTCOMES AND SERUM CONCENTRATIONS 
OF METHADONE 
 
ABSTRACT 
Introduction: Methadone maintenance therapy (MMT) has been widely used to prevent 
withdrawal symptoms among opiate use disorder patients. It is one of the harm 
reduction approaches in order to reduce the spread of fatally blood borne diseases in the 
community especially HIV AIDS. However, determining the optimal dose in patients is 
somehow difficult and challenging as it shows wide inter-individual variability of 
pharmacological activity. This study correlates the trough serum methadone 
concentrations (Ctrough) at steady state with the methadone dose and the clinical 
outcomes namely severity of withdrawal symptoms and urinalysis for other illicit drugs. 
The relationship between various CYP2B6 haplotypes with the Ctrough and OPRM1 
(A118G) single nucleotide polymorphisms (SNPs) with the clinical outcomes measures 
were also studied.  
Methodology: One hundred and fifteen (115) patients participated in the study after 
screening and signing the informed consent form. Blood samples were collected for 
genotype determination (once) and Ctrough determination (each data collection point). 
The methadone serum concentrations were analyzed by using ELISA (methadone 
ELISA kit) method and genotyping of CYP2B6 and OPRM1 (A118G) were determined 
by using validated PCR method. Statistical analysis was applied appropriately.  
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Results: Methadone dose was found to have moderate and positive correlation with the 
Ctrough (r=0.4, p<0.001) with only about 20% of changes in Ctrough can be explained by 
the changes in dose (r
2
=0.16-0.19, p<0.05) even after considering possible patients 
characteristics which may influence the two variables. Nevertheless, Ctrough have 
shown poor correlation with severity of withdrawal symptoms or urinalysis for other 
illicit drugs. Dose on the other hand did not show any correlation with both of the 
clinical outcomes measured. Study on CYP2B6 gene shows those patients with 
CYP2B6*6 variants have significantly higher mean of corrected trough serum 
concentrations (log Ctrough/dose) compared to the wildtype (CYP2B6*1). Further study 
on the OPRM1 (A118G) gene further shows those patients with homozygous variants 
(GG) did not involved in illicit drug use at lower methadone concentration of less than 
250ng/ml compared to the wildtype (AA) (p<0.05) 
Conclusion: CYP2B6 and OPRM1 gene with A118G SNPs may able to explain some 
of the variability in Ctrough and clinical outcomes measured in MMT. However, those 
genes may not be of value in therapeutic drug monitoring for the purpose of 
personalizing the dose of methadone as based on the clinical outcome measures. 
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CHAPTER 1 
INTRODUCTION & LITERATURE REVIEW 
 
1.1 Background  
“Opioid addiction is a curse wrapped-in a gift”, a perfect phrase from an opioid user 
which directly describes the rewarding and at the same time, the slow bringing forth of 
its addictive mechanisms, enclosing patients in a tunnel-like trap with nowhere to escape 
(Tasman et al., 2008). Popularly regarded a social or personal affliction, in the 1960s, 
opiate addiction was redefined a medical disease (Kreek, 1993; Kuehn, 2005). In the 
1990’s Dr Alan Leshner, a former director of the National Institute for Drug Abuse 
(NIDA) described opioid use disorder as an illness of the brain with suffers exhibiting 
untoward behavioural manifestations (Kreek, 1993). Understanding the pathophysiology 
and the treatment intervention of opioid use disorder was not traditionally of a priority. 
However, when studies consistently revealed the nestled relationship between 
intravenous drugs use (IDU) and the spread of human immunodeficiency virus (HIV) 
(D'Aquila & Williams 1987; Mascola et al., 1989; Schrager et al., 1991; Des Jarlais et 
al., 2003) it could no longer be ignored. In 2004, a study in 130 countries put the number 
of intravenous drugs users (IDUs) worldwide at approximately 13.2 million with 78% in 
developing and transitional countries. Prevalence of acquired immunodeficiency 
syndrome (AIDS) in these populations was estimated to be at least 20%. The virus 
spread mainly through the sharing of contaminated needles and other injection 
equipment but spread also occur through sexual intercourse, homosexual activity and 
mother to child transmission (Aceijas et al., 2004).  
2 
 
In 2009-2010, a worldwide study estimated that, worldwide, there were 15.9 million 
(11.0-21.2 million) IDUs and the highest percentage occurred in China, in the United 
States and in the Russian Federation. The average global prevalence of HIV/AIDS 
among IDUs was then estimated at 17.9%, with around 1 in 5 IDUs being HIV positive. 
Even though the global trend listed cannabis as the most widely used illicit drug, in Asia, 
opiates (nearly three quarters were heroin users) and other opioids were the most 
commonly used drugs implying a high proportion of IDU among drug users in the 
region (UNODC, 2011).  In Malaysia, heroin has been the major drug of abuse 
contributing to approximately 84.0% to the overall drug-use burden (Scorzelli, 1988). 
 
From their figures, in some countries, apart from it being the predominant role in 
transmitting the virus, injecting drug use also played a vital role in transmitting the virus 
to non-needle users. More transmission occurred from IDU compared to those from 
mother to foetus with a similar HIV prevalence observed among IDUs and non IDUs. 
IDUs probably transmitted HIV to their spouses through unsafe sex, thus their 
importance in HIV spread in people not using drugs. Thus, what probably started as a 
concentrated epidemic among IDUs has now showing evidence of generalization in the 
population (Strathdee & Stockman, 2010). In Malaysia and other countries in South East 
Asia, IDU is the major contributor to the HIV epidemic (Strathdee & Stockman, 2010). 
Parallel transmission of other blood-borne infections among IDUs adds a further 
complication with the added disease burdens of other fatal and contagious diseases like 
hepatitis B, C, and endocarditis (Chawarski et al., 2006; UNODC, 2011).  
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In Malaysia, due to its proximity to the “Golden Triangle” drug use disorder became 
very prominent and dated back to the 1960’s.  Recreational use of opiates in Malaysia 
and elsewhere peaked during the era of the “hippies” in the 1970’s (Kamaruddin, 2002). 
The numbers has since rapidly increased and in response, the Malaysian Government 
announced a war against drug use in 1983, similar to the approach in the US, probably 
then assuming Americans as having the most effective policy. Three acts-the Drug 
Dependants (Treatment and Rehabilitation) Act 1983- the Dangerous Drugs (Special 
Preventive Measures) Act 1985 and the Dangerous Drugs (Forfeiture of Property) Act 
1988 were legislated to curb the spread (Kamaruddin, 2002).  
 
The approach to drug use in Malaysia has been criminal as exemplified from its 
declaration of total war against its use. Malaysia has also displayed “zero-tolerance” to 
drug use and users and traffickers are generally treated similarly using its tough 
draconian drug laws, first introduced in 1983. In the main, drug use is considered a 
psychological/social problem that is self-inflicted (Rusdi, 2008). Thus, apart from 
criminalizing users, tremendous efforts are made at the “rehabilitation” of users and 
traffickers alike. In 1987, rehabilitation centres were built at great cost under the 
supervision of the Ministry of Home Affairs. Traffickers and users were then bundled 
into these and given the “cold turkey” treatment. They would usually remain there for up 
to two years, leading a regimented life of “rehabilitation” with the cold turkey, 
educational counselling, religious related teachings and preaches, as well as life skills 
enhancement programs bundled in. Pharmacological interventions were shunned 
although refractory subjects were given opioid antagonists such as naltrexone or 
naloxone to prevent craving (Mazlan et al., 2006).  
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After this period of “rehabilitation”, “rehabilitated” users would be discharged back to 
the society, almost with zero follow up.  Not surprisingly, many would return for “repeat 
rehabilitations”, some up to ten times. The number steadily increased and between the 
years 1983 to 1988, it ranged from 44.3 - 60.7%. This was despite reports of a 
decrement in the number of new users in 1988. Thus the continued use of the approach 
was questioned (Scorzelli, 1992; Rusdi, 2008). Other interventions taken by the 
Government included awareness programs, education and media campaign for the 
prevention of drug use, specifically targeting the young population and other vulnerable 
groups (Wah et al., 1996). Such remained the chosen policy until HIV became 
pandemic. 
  
The way drug use disorder was seen has changed little over time, not until HIV came 
into being. The world saw its “first” HIV infection in 1981 (Centre for Disease Control 
and Prevention, 2001) not too long before it grew to be a rapidly growing pandemic. 
HIV is blood-borne. How HIV is transmitted has changed little over time and includes 
penetrative sex (homo- or hetero-), mother-to-fetal transmission and blood transfusion 
from infected donors. The sharing of injection equipment among injecting drug users is 
however a very efficient means of HIV transmission. There occurs a direct transfer of 
blood between individuals who share needles and other injection paraphernalia. A close 
association between injecting drug users (IDUs) and the HIV pandemic then began to 
emerge as exemplified in a study in a drug use community in New York in 1987 where 
50% of the community became infected two years after the virus entered the community 
(Des Jarlais & Friedman 1989). When HIV entered the drug use community, its spread 
became explosive.  
5 
 
HIV first entered Malaysia in 1986. Soon after, its transmission became almost 
uncontrollable, peaking in 2003 with almost 24 new cases per 1000 population per year 
(AIDS/STI Section, Ministry of Health, Malaysia, 2012). Fueled by drug use, 
Malaysia’s pandemic quickly became the fastest growing epidemic in the Asia Pacific 
region. HIV control is the only failed WHO millennium goal for Malaysia (United 
Nations Country Team, 2010). According to the regional office of WHO Western 
Pacific Region in 2011, the proportion of people living with HIV/AIDS (PLWHA) in 
Malaysia was estimated at 0.3% of the overall population (69,000 out of 25,347,000). 
From those, 73.7% occurred among people who used drugs (PWUD), specifically IDU, 
due to their sharing of injecting equipment (WHO WPRO, 2011). More alarmingly, 
what started as a concentrated epidemic among IDU, the epidemic is now showing 
evidence of a generalized spread. Thus although women make up a very small portion of 
drug users in Malaysia, the proportion of them infected with the virus has increased to 
an alarming 100-fold in ten years. Despite of all the numbers and all the evidence, little 
changed in Malaysia as regards drug use. Drug users continued to be marginalized and 
put into prisons and rehabilitation centres, further feeding the epidemic where the prison 
and centres became places of concentrated epidemics that would eventually spread to the 
population. In February 2003, a group of activists forming the working group for harm 
reduction at the Malaysian AIDS Council (MAC) that was convened by Professor 
Adeeba Kamarudzaman, an HIV-physician at Universiti Malaya succeeded in presenting 
a case to the committee headed by the then Deputy Prime Minister (DPM), YAB Dato 
Sri Najib. Nevertheless and very unfortunately, the policy change that was approved at 
this meeting with the DPM did not actually roll out until 2006.  
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In the year, the country saw its first needle syringe exchange programme (NSEP) and  
opioid substitution therapy (OST) with methadone maintenance therapy (MMT) 
program coupled with outreach programs primarily targeting the high risk groups that 
included the drug use community (WHO WPRO, 2011). This actually occurred only 
after the MMT program tabled and approved in the Parliament in October 2005. As 
espoused by Dato’ Seri Najib, the primary responsibility for the program including its 
monitoring shifted to the Ministry of Health through the National Advisory Committee 
on AIDS and the Technical Committee on AIDS with the role of National Anti-drug 
Agency (AADK- Agensi Anti-dadah Kebangsaan) then relegated to being the 
secretariat. Soon after, promising results were seen (Ministry of Health (MOH) 
Malaysia, 2005). 
 
1.2 Methadone maintenance therapy (MMT). 
 
The use of methadone hydrochloride as maintenance therapy in opioid use disorder was 
initially proposed by Professor Vincent P. Dole and the late Professor Marie E. 
Nyswander in 1965. In their now famous study, MMT was shown to prevent and relieve 
opiate craving while blocking its euphoric effects (Dole & Nyswander, 1965). The take 
up of MMT however remained low because of critics and stigmas (Ausubel, 1966). 
Although the modality is now accepted in most of the world, MMT remains stigmatized 
and even now, more than 40 years after, methadone remains a widely studied drug 
(Kuehn, 2005).  
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His success with MMT prompted Dole to advance a new theory for opiate addiction, the 
opiate deficiency syndrome. Thus MMT was more a corrective rather than curative type 
of therapy, a normalising therapy. MMT normalizes the somatic, neurological as well as 
endocrinological dysfunction associated with prolonged opiate use. There is almost an 
immediate positive outcome seen with MMT where the patients exhibit a quick shift in 
their topic of interest that usually is centred on their next opiate dose such as from the 
time and context of their next opioid dose to more normal, leisurely topics and 
behaviours (Dole, 1988). Methadone also exerts a longer period of action which 
ultimately reduces fluctuations in serum concentrations, making it more convenient for 
both the patients and their physicians. Methadone is stored in the tissues and released 
slowly once there was a reduction in the serum level giving it a buffering characteristic. 
It has in fact been suggested that blood methadone be optimally maintained between 
150-600ng/ml to ensure its efficacy (Dole & Kreek, 1973).  
 
Several characteristics make methadone especially suitable for maintenance therapy 
(Kreek, 1993). Methadone exhibits an excellent oral bioavailability that ranges between 
80-90%. The drug also exhibits a long half-life allowing for a once daily dosing that can 
fit well into the patients’ daily life. Patients will be able to lead a normal lifestyle and 
maintain productivity, without the deliberating craving. Another important criterion of 
methadone is its slow onset of action, which prevents the fluctuations of drug 
concentrations in the blood and brain, preventing withdrawal symptoms. This allows for 
a steady state “perfusion” of the drug at its site of action on the specific opioid receptors 
and other sites involved.  (Kreek, 1993). 
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Although MMT is now generally accepted in most countries, practices vary. In countries 
like the USA and Malaysia, a “high-threshold” approach is taken where stringent 
guidelines and protocols dictate how MMT is to be implemented. As an example, under 
such an approach, a person can only be prescribed methadone if there is family support 
and patients can be expelled from the program if they breach the stringent program rules. 
These occur despite agreements that MMT is an essential component in managing the 
ongoing world-wide HIV epidemics.  
 
Thus, in the United States of America (USA) where its National Institute for Drug 
Abuse (NIDA) recognizes MMT as the main strategy to overcome the HIV/AIDS 
pandemics (NIDA, 2005), methadone is prescribed in its oral-form only and under close 
monitoring according to strict guidelines and protocols (Legislative Council Secretariat 
US., 1996). Such is regrettable as, it is known that even interim methadone clinics did 
show positive effects on the use of illicit drugs and HIV related risks behaviour even 
without the full and comprehensive methadone treatment in official programs. 
(Stanley,1991).  
 
In Canada, although MMT is adopted, they subscribe to the high-threshold approach 
with their comprehensive but stringent guidelines (New Brunswick Addiction Services, 
2009).  
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In countries like the United Kingdom (UK) and the Netherland on the other hand, a “low 
threshold” approach is adopted where there is a generally less stringent controls. The 
comfort and convenience are also given due considerations. As an example, patients 
could choose to take one of the several formulations of methadone available in the 
market according to their needs (daily illicit injectors, had poorer psychological and 
physical health at entry) (Ford & Whitehead, 1996; Strang et al., 2000).  Formulations 
included tablets, syrups or liquids and even intravenous routes where it has been shown 
to result in similar success rates in sub-populations of poorly responding patients given 
maximal doses of methadone.  
 
Unlike their counterparts in high-threshold programs who have to comply to the many 
stringent rules,  low-treshold regular/returning patients can have their prescription filled 
at the community pharmacies, saving them long waits at the clinics to see their doctors. 
They were also not required to be closely supervised as in the directly observed therapy 
(DOT) of the high-threshold patients (Gossop et al., 2001). The low-threshold is also 
adopted in Australia although political expediencies sometimes override good science. 
The MMT program in Australia has been very successful and together with their 
extensive NSEP coverage, it is regarded as the most effective approach in reversing their 
growing epidemic. Australia now has over 25,000 people on MMT and this has been 
touted as a successes story in policy decisions (Mc Arthur, 1999). 
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HIV knows no borders. Even the socialist/communist countries with their strict laws 
could not prevent the attacks of HIV. Thus in China for instance, where the actual 
numbers of PLWHA is anybody’s guess, HIV is also a major threat. Fortunately though, 
China boasts of probably having the most extensive program coverage with the highest 
number of MMT clinics that first begun in 2004 with 8 pilot methadone clinics (Liu Z. et 
al., 2006). Indeed, looking at their progress now, it is almost unbelievable that the 
Chinese came to learn from Malaysia when they were embarking on the program, and 
look at them now (Ismail, 2004), although there are concern about patients’ aftercare, 
unsatisfactory participation levels in training programmes for volunteers (Yin et al., 
2010). In Malaysia, according to the current practice guideline (MOH Malaysia, 2005) 
on initiating the dosage of methadone, upon enrolment, patients were subjected to 2 
phases of MMT; 1) Induction and 2) Maintenance phase. During induction phase, the 
dose is gradually increased until withdrawal ceases and the clinical response is 
satisfactory. A good history is vital as it gives information on previous methadone 
intake. It has also being recommended that patients should not be commenced with 
methadone in the case of no evidence of physical dependence in order to prevent the 
incidence of methadone intoxication. Generally physicians normally start treatment with 
a 20 - 40 mg daily dose of methadone, to be taken usually in the morning. During the 
initial week or two, dosage increments were kept relatively low, typically 5 
mg/increments every 3 days as clinically indicated. Patients are followed up closely, 
every day or every other day during the first several weeks, for efficacy as well as 
toxicity. Fresh urine samples were also obtained to screen for abstinence. Up to a month 
is required before a steady-state is reached after which there would be less fluctuation in 
blood methadone. 
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The guidelines call for strict monitoring of the patients and during the maintenance 
phase, they would be reviewed every month and their urine tested randomly for illicit 
drugs. Outcomes were measured using several instruments; the WHO-BREF Quality of 
Life, Opiate Treatment Index (OTI) with urine tests for illicit drugs (methamphetamine, 
amphetamines, ketamine, tetrahydrocannabinoids and the benzodiazepines that included 
midazolam and alprazolam). Apart from the MMT, supportive therapy was also given in 
an effort to enhance the success rate of therapy (Brooner & Kidorf, 2002).  
 
Patients would be given counselling with either the pharmacists and/or designated 
counsellors and they were also monitored for toxicity. Of note are some characteristics 
of the patients that may also impact on their therapy. Generally these patients have 
greater illicit drugs exposure, higher rates of psychiatric diagnoses and other medical 
conditions, high rates of unemployment together with low psychosocial status. 
Furthermore, peer pressure associated with the drug culture in the community may make 
it difficult for the patients lead a drug-free life, even legally (Brooner & Kidorf, 2002).  
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1.3 Pharmacology 
Methadone is a synthetic drug with a full µ-opioid receptor agonistic property. It is 
classified as opioid analgesics / opioids (Micromedex online database). Clinically, 
methadone has been used in the chronic treatment of moderate to severe pain and also in 
the management of opiates dependence (Fredheim et al., 2002 ; Eap et al., 2002) which 
is our focus in this study.  
 
 
Figure 1.1: Chemical structure of methadone 
(Source : Martindale. Complete Drug Reference) 
 
Isolated methadone is liposoluble and basic with pKa of 9.2 that also gives it buffering 
properties as seen during its initial discovery (Dole & Kreek, 1973 ; Garrido & 
Troconiz, 1999). Oral bioavailability is highly variable and reported to range from 41% - 
95 % (Meresaar et al., 1981; Ferrari et al., 2004) with large inter-subjects variation. At 
doses between 10-60 mg, oral bioavailability of its tablet lies between 70-80% (Eap et 
al., 2002) and this contributes to inter-subject variability which is important for the 
determining of the initial and maintenance doses.  
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Methadone plasma concentrations over time follow a bi-exponential curve, with a rapid 
α-phase (the transfer of the drug from the central compartment to the tissue compartment 
and to the beginning of elimination) and a slow β-phase that corresponds to elimination 
(Ferrari et al., 2004). As it has a rapid α-phase, the kinetics of oral methadone at steady 
state has been described as following a single compartment model (Wolff et al., 1993).  
The t1/2α (α-phase) shows marked inter-individual variability, and ranges from 1.9 to 4.2 
hours (H), with an average value of 2.95 ± 0.9 H (Meresaar et al.,1981). The t1/2β of 
elimination (β-phase) varies even more, from 8.5 to 47 H (Nilsson et al., 1982a; Wolff et 
al., 1991). It is widely accepted that the population half life of methadone was between 
24 ± 13 H (Eap et al., 2002). 
 
Methadone is prescribed as a racemic mixture of two stereoisomers. Apart from other 
pharmacological effects, (R)-methadone is responsible for analgesia but (S)-methadone, 
while retaining some of the effects like the antitussive activity (Ferrari, 2004) is 
responsible for some of the methadone toxicity, namely cardiac arrythmias. Several 
formulations are available; solution (syrup-based), tablet and injectable for intravenous 
(IV) or intramuscular (IM) injection. Absorption from tablets and syrup appear 
comparable (Meresaar et al., 1981). It is expected that there will be no significant 
difference between oral formulations in terms of their pharmacokinetics profile (Eap et 
al., 2002)  
 
After oral administration, onset of action is variable but typically it occurs after about 
two hours. Its duration of action, again, although variable, it is typically between 2-10 
hours after the dose (Dale et al., 2002) and so is the time to peak concentration that 
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varies between 2-4 hours (Inturrisi & Verebely, 1972 (b); Verebely & Kutt., 1975). 
Enterohepatic recirculation of methadone is probably responsible for the second peak 
which occurs approximately 4 hours after its administration (Eap et al., 2002). 
Methadone can be detected in the blood within 15–45 minutes after an oral 
administration (Wolff et al., 1993; Inturrisi et al., 1972; Ferrari et al., 2004).  
 
Methadone is highly bound to plasma proteins, including to albumin, γ-globulins, 
lipoproteins and the most prominent one is α1-acid glycoprotein (Foster et al., 2004; Eap 
et al., 2002). Protein binding is about 71-89% (Olsen, 1973) that varies depending on 
serum protein concentration (Horns et al., 1975). As an example, acute phase protein, 
α1-acid glycoprotein will increase during pathological conditions such as cancer and 
long term opioid exposure. This explains a lower free fraction of methadone in cancer 
patients than in control subjects. Eap et al. reported that methadone free fraction have 
shown 3-6 fold in variability depending on patients’ conditions (Eap et al., 2002). 
 
Due to its high lipid solubility, methadone rapidly attains high tissue concentrations in 
the kidneys, spleen, liver and lungs and a smaller amount goes into the brain (Blinick et 
al., 1974) almost simultaneously (Ferrari et al., 2004). Methadone also readily crosses 
the placenta. However, the exposure of breast-fed infants to methadone consumed by 
their mothers is minimal. Women on MMT should therefore not be discouraged from 
breast feeding because of this (Wojnar-Horton et al., 1997). In general, its volume of 
distribution (VD) is about 1-8L/kg (Micromedex online database). It has been found that 
oral clearance and VD of racemic methadone were not influenced by body weight over 
the 44-110kg range, even when allometrically scaled (Foster et al., 2004).  
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Methadone is extensively metabolized and mainly in the liver. Small amounts undergo 
gut metabolism mediated by intestinal CYP3A4. The main metabolite of methadone (2-
ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine; EDDP) is inactive and it is formed by 
N-demethylation with a subsequent spontaneous cyclization (Ferrari et al., 2004). Other 
than methadone and EDDP, eight other metabolites have been identified in the urine, 
and three metabolites in the faeces (Eap et al., 2002).  
 
Subsequent to the biotransformation, methadone is eliminated in the kidneys as well as 
the faeces. In a study conducted with four subjects given radio-labelled methadone, two 
of the subjects excreted the major part of the radioactivity in the urine with the other two 
eliminating the radioactivity in both urine and faeces (Eap et al., 2002). The rate of renal 
clearance was approximately 2.9-15.6 ml/min (Inturrisi & Verebely, 1972(a)). 
Methadone and EDDP together account for 17–57% of a given dose, 15–60% during the 
first 24 hours (20% as an unmodified drug, and 13% as 2-ethylidene-1,5-dimethyl-3,3-
diphenylpyrrolidine; EDDP).  
 
Faecal elimination accounts for 20–40% of the total elimination. Overall faecal 
elimination accounts for about 25% of total elimination during the first 24 hours, and 
52% during the first 96 hours (58% as methadone and 42% as metabolites). Urinary 
elimination of unmodified methadone is pH-dependent and is increased by urine 
acidification. When urinary pH is less than 6, the amount of excreted methadone is three 
to eight-times greater than at pH higher than 6 (Ferrari et al., 2004).  
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The elimination of methadone is mostly due to a metabolic clearance. The limited 
amounts of circulating drug that undergoes glomerular filtration are partially reabsorbed 
by the kidney tubules, and this re-absorption is also pH-dependent. In one study, a 3-fold 
higher renal clearance was calculated in a group of patients with a 24-hour urine pH of 
6.1 as compared to another group with a 24-hour urine pH of 6.6  (Foster et al., 2004). 
 
1.4   Clinical Use 
 
The treatment of drug use disorder prevents HIV/AIDS (Sorensen & Copeland, 2000) 
and clinical trials have shown its effectiveness especially in terms of reducing HIV 
seroprevalence and transmission of other blood-borne viruses. Two decades of study in 
the Bronx in New York on MMT has shown that methadone was effective as a 
protective measure in cutting down the number of HIV infection (Hartel & Schoenbaum, 
1998).  Positive outcomes included a reduction of illicit drug use which in itself will 
reduce HIV AIDS risks due to reduction injecting frequencies (Bloor et al., 2008; 
Marsden et al., 2009) and a reduction in needle sharing which again protects against 
HIV/AIDS. 
 
MMT is a life-long commitment. The longer the patients receive MMT the better the 
outcome and this has been used by detractors who saw MMT simply as replacing one 
dependency with another (Gossop et al., 2003). A longitudinal prospective cohort study 
showed a long term continuous improvement in the quality of life of patients on long 
durations that ranged from 3 to 12 months and this has also supported long term use of 
the treatment (Maremmani et al., 2007
b
). 
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The benefits are maintained in patients with psychiatric co-morbidity who also showed 
improvements including longer treatment retention, reduction of illicit drug use and 
reduction in HIV-related risks behaviour (Pani et al., 1997). Similarly, providing 
methadone in incarcerated settings are also effective but the therapy has to be continued 
post-release (Kinlock et al., 2009). 
 
Gossop et al. has undertaken a big study called the National Treatment Outcome 
Research Study (NTORS). The majority of patients in the study demonstrated 
improvements in each domain measuring illicit drug use, criminal behaviour, withdrawal 
symptoms, HIV AIDS risk behaviour, health status and overall socioeconomic position 
as well as quality of life (Gossop et al., 2000). A similar study conducted in Malaysia 
produced similar trends of success with improvements in the quality of life in patients 
undergoing MMT. Retention rate was 63.6% after 2 years and significant improvements 
were documented in terms of physical and psychological health, socio-economic status 
and existence of supportive environment (p<0.001) (Musa et al., 2011).  
 
Take home privileges may encourage retention as it reduces the burden and stress of 
patients having to attend daily methadone clinics. The rule which prohibits the take-
home doses has a negative consequence (Pani et al., 1996). Take-home doses among 
highly motivational and stable patients even increased patients’ incomes when compared 
patients who have to comply to rigid daily scheduled observed therapy (King et al., 
2002).  
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In general, the case for the effectiveness of MMT has been strongly made. MMT is of 
proven benefits in decreasing the following: relapse; number of days using illicit 
opioids; usage of opioid and cocaine after release from prison; criminal activity; 
injection and HIV transmission activity. MMT also increased employment rate; proven 
cost effective; improved retention rates in HIV care; improved the use and effectiveness 
of highly active anti retroviral therapy (HAART) (Altice et al., 2010). 
 
On the flip side, several studies failed to demonstrate the effectiveness of MMT in 
specific populations as measured by degree of drop outs, dose deviation, violation of 
rules and regulation under methadone programs, death due to overdose, suicide which 
has been confirmed by autopsy as well as transfers to centres which serve heroin. These 
occurred mainly with patients who continued taking illicit heroin despite being under 
MMT (Mino et al., 1998). In European countries, the continuous use of cocaine and 
alcohol continue to threaten the success of MMT (Maremmani et al., 2007
a
). Cocaine 
use during treatment has been shown to be detrimental to treatment retention and 
promoted heroin relapse (Hartel & Schoenbaum, 1995) and alcohol dependence 
frequently occurred as co-dependence (Hillebrand et al., 2001).  
 
Used safely in millions over the years, MMT is relatively safe. Nevertheless it has been 
associated with some very serious adverse effects, the most serious of which is probably 
the precipitation of QTc-prolongation. The prolongation can herald the occurrence of 
potentially fatal arrhythmias including torsade des pointes (Justo, 2006; Anchersen et 
al., 2009; Mayet et al., 2010).  
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Respiratory distress and neuropsychology impairment can also occur. These may occur 
after prolonged use of methadone and has led to the sudden discontinuity of treatment 
and treatment failures. Nevertheless, despite these, MMT has been shown to be 
consistently superior to other approaches that include drug-free forced abstinence 
(Prosser et al., 2006). 
 
Poor adherence indicates a failure to achieve the goal of therapy and among others, it 
has been associated with unsupervised methadone prescribing and consumption 
(Haskew et al., 2008). Poor adherence is however contentious. Some authors suggested 
measuring EDDP as a means to assess compliance (Larson & Richards, 2009).  
 
Many factors contribute to the failure of methadone treatment and effectiveness. Among 
others, as has been shown in many studies, failure to use sufficiently high methadone 
doses has been reported to importantly contribute to treatment failures (Capplehorn et 
al., 1993; Mino et al., 1998; Leavitt et al., 2003). Indeed using an optimal dose is the 
key to successful MMT. However determining an optimal dose is a major challenge 
(Hiltunen et al., 1999; Trafton et al., 2006). Many studies have in fact showed that low 
doses caused treatment failures. It is our objective in this study to determine factors that 
can contribute to treatment failures and further optimize the dosing regimen. 
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1.5  Dose Optimization 
 
Methadone has a complex disposition mediated by polymorphic enzymes, transporters 
and receptors. The consequent pharmacokinetic variability makes similar doses not 
yielding similar plasma concentrations or clinical effects in different subjects. Its long 
half-life and wide inter-patient variability in its clearance also make methadone use 
difficult to optimize. These variability may be further altered by drug interactions.  
 
Patients on MMT frequently receive treatment with other drugs due to the frequent 
comorbidity. Common are the use of psychotropic drugs, antibiotics, anticonvulsants 
and antiretroviral drugs and these can cause pharmacokinetic interactions. The 
consequent pharmacokinetic drug–drug interactions with methadone can reduce the 
concentrations and the effects of methadone with the consequent withdrawal and 
increased risks of relapse. Justified or otherwise, due to fears of high doses and the 
occurrence of toxicity, many physicians use relatively low doses of methadone in MMT. 
The use of low doses threatens to derail successful MMT programs. 
 
As a surrogate for effectiveness, Dole and Nyswander have long proposed the use of 
therapeutic drug monitoring for MMT and they recommended that blood concentration 
be maintained around 150-600 ng/ml for effectiveness (Dole & Kreek., 1973). 
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1.5.1  High dose yields better outcome 
 
“Higher is better”. That generally holds through with methadone maintenance dose to 
ensure retention in programs, up to a limit. As an example, it was found that a dose of 50 
mg/day was associated with higher retention rates compared to lower doses (Farre M. et 
al., 2002). Similarly, patients maintained on 60 mg/day or higher had better treatment 
outcomes and indeed, doses exceeding 100 mg/day have been used safely and 
effectively in long-term maintenance treatments (Maxwell & Shinderman, 2002).  
 
The odds of patients maintained on 40 mg were 2.2 times more likely to be back on 
heroin use compared to those maintained on 80 mg daily (Caplehorn et al., 1993).  
 
A study by Hartel et al. further concluded that the use of high methadone doses is 
important to promote heroin abstinence. They found that heroin use during the 3 months 
prior to study interviews was highest among (1) patients maintained on less than 70 
mg/day (adjusted odds ratio [OR] = 2.1, 95% confidence interval [CI] = 1.3, 3.4) and (2) 
patients who used cocaine during treatment (adjusted OR = 5.9, 95% CI = 3.8, 9.1). 
They further reported that these were independent of treatment duration, treatment 
compliance, alcohol use, and socioeconomic factors. Cocaine users were more likely 
than non-users to use heroin at all methadone dosage levels (Hartel et al., 1995).  
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Similarly, yet another study reported that patients on higher doses (more than 70mg/day) 
had a better prognostic outcome in terms of retention rates and illicit opioid use, even 
though the authors also reported a similar role for other factors that included the quality 
of interpersonal relationships, stable income and low withdrawal scores that yielded a 
better prognostic outcome (Gerra et al., 2003). Similar observations were also reported 
in other studies that included those by Ball & Rose, (1991); Maremanni et al., (1994);  
Mohamad et al., (2010). 
 
On the contrary, several studies failed to find a clear association between positive 
treatment outcomes and high doses. In Canada for instance, both higher and lower 
dosage protocols have been clinically implemented with parallel end results in different 
populations. Older and more motivated patients were given the low dose (40 mg) 
whereas higher doses (100 mg) were given to less motivated and more chronic users 
(Williams et al., 1971).   
 
In an earlier study (Craig, 1980) where a dose of  30 mg daily was used, it was reported 
that patients remained on treatment for 6 to 12 months and scored higher in terms of 
outcomes, such as reduced illicit heroin consumption, reduced arrest due to criminality 
and full-time employment compared to the dropouts (Craig, 1980) even at this low dose.  
Other studies reported continuing use of illicit drugs and cravings despite high 
methadone dosage (deVos et al., 1995). In yet another study by Blaney & Craig (1999), 
reported lack of significant difference in any of the outcome variables attributable to 
methadone doses (Blaney & Craig 1999). 
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Based on the above, it has been suggested that the dosage of methadone should be 
individualized instead of relying solely on the study population. Mino et al., (1998) 
proposed the use of individualized doses in concert with psychosocial support to 
increase success rates of MMT. They suggested that flexibility in methadone doses will 
lead to improved retentions as compared to rigid and population-based doses. However, 
it has been suggested that patients who have responded well to doses less than 30 mg 
should have no reason to increase their doses (Mino et al., 1998) but there may be a case 
for stopping MMT altogether in the patients because it is conceivable that the patient 
does not require MMT at all.  
 
Methadone dose increase and abstinence reinforcement have been reported to decrease 
urine positive tests during treatment. However, it is probably best to give doses to 
individual patients’ needs (Preston et al., 2000). Alas, evidence may not translate to 
practice and many physicians continue to prescribe low doses, probably for 
psychological reason (Loimer & Schmidt, 1992).  In Malaysia average dose is less than 
40 mg per day but we recently showed that even in Malaysia, a daily dose of 80 mg was 
superior to lower daily doses (Mohamad et al., 2010). 
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1.5.2 Methadone concentrations and TDM for methadone 
 
As with many other drugs with low therapeutic indices, therapeutic drug monitoring 
(TDM) with use of plasma methadone may help in dose optimization for MMT to 
improve outcomes. A therapeutic range of 300 - 400 ng/ml racemic methadone has been 
proposed (Torens et al., 1998). Wolff et al., (1991) have indeed proposed a dosage 
nomogram for improved application of MMT. They found a good correlation between 
dose and serum methadone concentration with an r of 0.89.  They then proposed that 
plasma methadone increased by 0.263 mg/L for every milligram of methadone 
consumed per kilogram of body weight (Wolff et al., 1991).  
 
Generally though, clinical practice can probably not now benefit from TDM due to a 
lack of suitable analytical methods. General application needs to await for an analytical 
method that, not only it is sensitive and specific but are also easy to perform by non-
experts. Currently methadone concentrations can only be determined using relatively 
sophisticated equipments and published methods include gas or liquid chromatography 
and immunoassay. (Wolff et al., 1992;  Schmidt et al., 1993;  Kell & Techman, 1996).  
 
Bell et al. in the 1990’s, suggested that the continued use of illicit drugs despite MMT 
were due to the patient’s desire to seek “desired” effects of methadone. It had nothing to 
do with either the drug dose or concentration. Their patients with lower serum 
concentration seemed to similarly have adequate methadone doses as did their patients 
with higher concentration. (Bell et al., 1990).   
 
